Search results
Showing 736 to 750 of 8938 results
This quality standard covers blood transfusion and reducing the requirements for blood transfusion in adults, young people and children aged 1 year and over. It describes high-quality care in priority areas for improvement. It does not cover use of tranexamic acid for surgery during pregnancy or labour or blood transfusion during pregnancy or labour.
View quality statements for QS138Show all sections
Sections for QS138
This quality standard covers the diagnosis and management of cataracts, glaucoma and age-related macular degeneration (AMD) and the prevention of sight loss. It describes high-quality care in priority areas for improvement.
View quality statements for QS180Show all sections
Sections for QS180
- Quality statements
- Quality statement 1: Referral – chronic open angle glaucoma and related conditions
- Quality statement 2: Referral for cataract surgery
- Quality statement 3: Treatment – late age-related macular degeneration (wet active)
- Quality statement 4: Monitoring late age-related macular degeneration (wet active)
- Quality statement 5: Reassessment – chronic open angle glaucoma or related conditions
- Quality statement 6: Certificate of vision impairment
- Update information
In development Reference number: GID-NG10443 Expected publication date: 25 March 2026
In development Reference number: GID-IPG10404 Expected publication date: 25 March 2026
Surgical insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock
In development Reference number: GID-IPG10461 Expected publication date: 25 March 2026
In development Reference number: GID-IPG10318 Expected publication date: 25 March 2026
Mitapivat for treating pyruvate kinase deficiency (terminated appraisal) (TA867)
NICE is unable to make a recommendation on mitapivat (Pyrukynd) for treating pyruvate kinase deficiency in adults because Agios did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA867
NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after a previous anti-HER2-based regimen in adults. This is because Daiichi Sankyo UK did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA879
NICE is unable to make a recommendation on semaglutide (Wegovy) for managing overweight and obesity in young people aged 12 to 17 years because Novo Nordisk did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA910
NICE is unable to make a recommendation on esketamine (Spravato) for treating major depressive disorder in adults at imminent risk of suicide because Janssen did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA899
Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) (TA901)
NICE is unable to make a recommendation on cemiplimab (Libtayo) for treating recurrent or metastatic cervical cancer in adults because Sanofi did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA901
NICE is unable to make a recommendation on ciltacabtagene autoleucel (Carvykti) for treating relapsed or refractory multiple myeloma in adults. This is because Janssen withdrew its evidence submission for the appraisal. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA889
NICE is unable to make a recommendation on capmatinib (Tabrecta) for treating advanced non-small-cell lung cancer with MET exon 14 skipping in adults. This is because Novartis Pharmaceuticals did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA884
NICE is unable to make a recommendation on decitabine–cedazuridine (Inaqovi) for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable. This is because Otsuka Pharmaceuticals (UK) did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA932
NICE is unable to make a recommendation on tisagenlecleucel (Kymriah) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic therapies. This is because Novartis did not provide a complete evidence submission.
Show all sections
Sections for TA933